These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 26774176)

  • 21. Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies.
    Jonsdottir T; Forslid J; van Vollenhoven A; Harju A; Brannemark S; Klareskog L; van Vollenhoven RF
    Ann Rheum Dis; 2004 Sep; 63(9):1075-8. PubMed ID: 15066863
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects.
    Iannone F; Trotta F; Montecucco C; Giacomelli R; Galeazzi M; Matucci-Cerinic M; Ferri C; Cutolo M; Maria Bambara L; Triolo G; Ferraccioli G; Valentini G; Lapadula G;
    Ann Rheum Dis; 2007 Feb; 66(2):249-52. PubMed ID: 16837489
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France.
    Saint Marcoux B; De Bandt M;
    Joint Bone Spine; 2006 Dec; 73(6):710-3. PubMed ID: 17127088
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.
    Schabert VF; Watson C; Joseph GJ; Iversen P; Burudpakdee C; Harrison DJ
    J Manag Care Pharm; 2013 Oct; 19(8):621-30. PubMed ID: 24074008
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Etanercept--infliximab switch in rheumatoid arthritis 14 out of 131 patients treated with anti TNFalpha].
    Brocq O; Plubel Y; Breuil V; Grisot C; Flory P; Mousnier A; Euller-Ziegler L
    Presse Med; 2002 Nov; 31(39 Pt 1):1836-9. PubMed ID: 12496713
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Of patents and patent disputes - The TNFα patent files. Part 2: Enbrel, Remicade, Cimzia and Simponi.
    Storz U
    Hum Antibodies; 2018 Feb; 26(2):49-61. PubMed ID: 29439320
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
    Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
    Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Older anti-TNF-α agents: why not group them for common indications in the EU?
    Garattini L; Ghislandi F; Padula A
    Expert Rev Pharmacoecon Outcomes Res; 2016; 16(1):1-4. PubMed ID: 26751100
    [No Abstract]   [Full Text] [Related]  

  • 29. Periprosthetic Joint Infection in Patients Receiving TNFα Antagonists.
    Snir N; Schwarzkopf R; Sobieraj M; Lovy AJ; Slover JD
    Bull Hosp Jt Dis (2013); 2014; 72(4):253-8. PubMed ID: 25986347
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumour necrosis factor-alpha blockers in rheumatoid arthritis: review of the clinical experience.
    Richard-Miceli C; Dougados M
    BioDrugs; 2001; 15(4):251-9. PubMed ID: 11437690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Persistence of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: An analysis of the South Korean National Health Insurance Database.
    Lee MY; Shin JY; Park SY; Kim D; Cha HS; Lee EK
    Semin Arthritis Rheum; 2018 Feb; 47(4):485-491. PubMed ID: 28939234
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of tumor necrosis factor alpha antagonists in a patient with rheumatoid arthritis and primary biliary cirrhosis.
    Spadaro A; Scrivo R; Riccieri V; Valesini G
    Joint Bone Spine; 2008 Jan; 75(1):87-9. PubMed ID: 17890133
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of serum anti-tumour necrosis factor (TNF) drug trough concentrations and antidrug antibodies (ADAb) to further anti-TNF short-term effectiveness after switching in rheumatoid arthritis and axial spondyloarthritis.
    Vincent FB; Pavy S; Krzysiek R; Lequerré T; Sellam J; Taoufik Y; Mariette X; Miceli-Richard C
    Joint Bone Spine; 2016 Oct; 83(5):595-7. PubMed ID: 27066773
    [No Abstract]   [Full Text] [Related]  

  • 34. Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases.
    Silvagni E; Bortoluzzi A; Carrara G; Zanetti A; Govoni M; Scirè CA
    BMJ Open; 2018 Sep; 8(9):e021447. PubMed ID: 30206082
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Which TNF inhibitor for rheumatoid arthritis?
    Med Lett Drugs Ther; 2010 May; 52(1338):38-9. PubMed ID: 20467356
    [No Abstract]   [Full Text] [Related]  

  • 36. Paradoxical psoriatic arthritis in a patient with rheumatoid arthritis treated by TNFα blocker.
    Villani AP; Weiler L; Jullien D; Chapurlat R; Confavreux C
    Joint Bone Spine; 2014 Oct; 81(5):455-6. PubMed ID: 24561024
    [No Abstract]   [Full Text] [Related]  

  • 37. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept.
    Lee JH; Slifman NR; Gershon SK; Edwards ET; Schwieterman WD; Siegel JN; Wise RP; Brown SL; Udall JN; Braun MM
    Arthritis Rheum; 2002 Oct; 46(10):2565-70. PubMed ID: 12384912
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug survival and causes of discontinuation of the first anti-TNF in ankylosing spondylitis compared with rheumatoid arthritis: analysis from BIOBADABRASIL.
    Fafá BP; Louzada-Junior P; Titton DC; Zandonade E; Ranza R; Laurindo I; Peçanha P; Ranzolin A; Hayata AL; Duarte A; Silveira IG; Costa I; Macieira JC; Guedes-Barbosa LS; Bertolo MB; Sauma MF; Silva MB; Freire M; Scheinberg MA; Fernandes V; Bianchi W; Miranda JR; Pinheiro GR; Carvalho HM; Brenol CV; Pereira IA; de Castro GR; de Morais JC; Oliveira SK; de Abreu MM; Toledo RA; Pinheiro MM; Vieira WP; Valim V;
    Clin Rheumatol; 2015 May; 34(5):921-7. PubMed ID: 25851594
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of Three Assays to Quantify Infliximab, Adalimumab, and Etanercept Serum Concentrations.
    van Bezooijen JS; Koch BC; van Doorn MB; Prens EP; van Gelder T; Schreurs MW
    Ther Drug Monit; 2016 Aug; 38(4):432-8. PubMed ID: 27120178
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Inhibitors of TNFalpha].
    Brousse C
    Rev Med Interne; 2003 Feb; 24(2):123-6. PubMed ID: 12650894
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.